Item 1.01.Entry Into a Material Definitive Agreement. On March 24, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Cowen shares of the Company’s common stock (the “Common Shares”). The issuance and sale, if any, of the Common Shares by the Company under the Sales Agreement will be made pursuant to a prospectus supplement, dated March 24, 2023, to the Company’s registration statement on Form S-3ASR, originally filed with the Securities and Exchange Comm(…)
The Latest Press Releases